

Applicant(s):	<b>Michael W. Miller</b>	:	Group Art Unit: <b>To be assigned</b>
Serial No.:	<b>To be assigned</b>	:	Examiner: <b>To be assigned</b>
Filed:	<b>To be assigned</b>	:	
For:	<b>CCR5 Antagonists Useful For Treating AIDS</b>	:	Attorney Docket No. : <b>IN01415K1B</b>
		:	
		X	

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Pursuant to Rule 56, it is requested that the documents listed on the accompanying PTO-1449 Form be considered and made of record in the above-identified patent application. Copy(ies) of these references ☐ are attached ☒ were filed in related application U.S. Serial No(s) **10/107,940** filed **March 27, 2002**, respectively.

☐ This Information Disclosure Statement is being filed within three (3) months of the filing date of the application.

☒ This Information Disclosure Statement is being concurrently filed with the above-identified application.

☐ This Information Disclosure Statement is being concurrently filed with a Request for Continued Examination (RCE).

☐ This Information Disclosure Statement is being filed prior to the mailing of a first Office Action on the merits.

☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or

☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; or


40953 1.DOC

- (d) ☐ This Information Disclosure Statement is being filed on or before the payment of the issue fee; and
- ☐ Each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement; or
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this Information Disclosure Statement; and
- ☐ The Commissioner is hereby authorized to charge the requisite fee listed on the attached Fee Transmittal Sheet.
- ☐ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. **19-0365**, Patent Case No. **IN01415K1B**. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,  
SCHERING-PLOUGH CORPORATION

Dated: **February 6, 2004**  
SCHERING-PLOUGH CORPORATION  
Patent Department, K-6-1, 1990  
2000 Galloping Hill Road  
Kenilworth, NJ 07033-0530  
Facsimile No.: (908) 298-5388

By: \_\_\_\_\_

  
Name: **Anita W. Magatti**  
Reg. No.: **29.825**  
**Attorney of Record**  
Telephone No.: (908) 298-5067

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE <b>INFORMATION DISCLOSURE STATEMENT          BY APPLICANT</b> <i>(Use several sheets if necessary)</i>		ATTY. DOCKET NO.: IN01415K1B APPLICANT: Michael W. Miller FILING DATE: To be assigned		SERIAL NO.: To be assigned GROUP: To be assigned		
<b>U.S. PATENT DOCUMENTS</b>						
*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	5,883,096	3/16/99	Lowe et al	514	
	AB	5,889,006	3/30/99	Lowe et al	519	
	AC	6,037,352	3/14/00	Lowe et al	514	
	AD	5,952,349	9/14/99	Asberom et al	514	
	AE	5,977,138	11/2/99	Wang et al	514	
	AF	6,066,636	5/23/00	Kozlowski et al	514	
<b>FOREIGN PATENT DOCUMENTS</b>						
	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	WO 00/66559	11/9/00	WIPO		
	AM	WO 00/66558	11/9/00	WIPO		
	AN	WO 99/04794	2/4/99	WIPO		
	AO	WO 97/24324	7/10/97	WIPO		
	AP	WO 97/16440	5/9/97	WIPO		
	BL	WO 94/18192	8/18/94	WIPO		
	BM	1 103 276	6/28/00	Europe		
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>						
	AQ	Vandamme et al, <u>Antiviral Chemistry and Chemotherapy</u> , <u>9</u> (1998) p. 187-203				
	AR	Connor et al, <u>Virology</u> , <u>206</u> (1995) p. 935-944				
	AS	Plater-Zyberk et al, <u>Immunol. Let.</u> , <u>57</u> (1997) p. 117-120				
	AT	Boiardi et al, <u>Clinical and Experimental Rheumatology</u> , <u>17</u> , (1999) p. 419-425				
	AU	Hatano et al, <u>Clin. Exp. Immunol.</u> , <u>117</u> (1999) p. 237-243				
	AV	Raychaudhuri et al, <u>International J. of Immunopharmacology</u> , <u>20</u> (1998) p. 661-667				
	AW	Chihara et al, <u>J. Allergy Clin. Immunol.</u> , <u>100</u> , 6, part 2 (1997) p. S52-S55				
	AX	Beck et al, <u>J. Immunol.</u> , <u>159</u> , 6 (1997) p. 2962-72				
	AY	Tagat et al, <u>Bioorganic &amp; Medicinal Chemistry Letters</u> , <u>11</u> (2001) 2143-2146.				
EXAMINER			DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						